[go: up one dir, main page]

DK3412660T3 - Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme - Google Patents

Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme Download PDF

Info

Publication number
DK3412660T3
DK3412660T3 DK17747622.3T DK17747622T DK3412660T3 DK 3412660 T3 DK3412660 T3 DK 3412660T3 DK 17747622 T DK17747622 T DK 17747622T DK 3412660 T3 DK3412660 T3 DK 3412660T3
Authority
DK
Denmark
Prior art keywords
same
pharmaceutical composition
composition containing
sulfonamide derivative
sulfonamide
Prior art date
Application number
DK17747622.3T
Other languages
English (en)
Inventor
Munetaka Tokumasu
Masatsugu Noguchi
Mizuki Kawahira
Kana Iwasaki
Nobuhiko Hayakawa
Wataru Miyanaga
Yuki Saitou
Yui YAMAURA
Ayatoshi Ando
Atsushi Tsuruta
Misato Noguchi
Original Assignee
Ea Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co Ltd filed Critical Ea Pharma Co Ltd
Application granted granted Critical
Publication of DK3412660T3 publication Critical patent/DK3412660T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17747622.3T 2016-02-05 2017-02-06 Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme DK3412660T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016021053 2016-02-05
PCT/JP2017/004278 WO2017135472A1 (ja) 2016-02-05 2017-02-06 スルホンアミド誘導体及びそれを含有する医薬組成物

Publications (1)

Publication Number Publication Date
DK3412660T3 true DK3412660T3 (da) 2020-11-30

Family

ID=59500204

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17747622.3T DK3412660T3 (da) 2016-02-05 2017-02-06 Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme

Country Status (16)

Country Link
US (1) US10562898B2 (da)
EP (1) EP3412660B9 (da)
JP (1) JP6820282B2 (da)
KR (1) KR102870086B1 (da)
CN (1) CN108699008B (da)
AU (1) AU2017214589B2 (da)
CA (1) CA3013433A1 (da)
DK (1) DK3412660T3 (da)
EA (1) EA036432B1 (da)
ES (1) ES2856125T3 (da)
HU (1) HUE053354T2 (da)
MX (1) MX381970B (da)
PL (1) PL3412660T3 (da)
PT (1) PT3412660T (da)
TW (1) TWI730042B (da)
WO (1) WO2017135472A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331559B1 (en) 1998-10-26 2001-12-18 The Research Foundation Of State University Of New York At Stony Brook Lipoic acid derivatives and their use in treatment of disease
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ucb製藥有限公司 (氮雜)吲哚-和苯並呋喃-3-磺醯胺類
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
PL3873605T3 (pl) 2018-10-30 2025-03-03 Gilead Sciences, Inc. Związki hamujące integrynę alfa4beta7
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
TW202330490A (zh) 2021-10-05 2023-08-01 日商Ea製藥股份有限公司 化合物或其藥學上所容許之鹽的製造方法
CN120897744A (zh) 2023-04-06 2025-11-04 Ea制药株式会社 含有磺酰胺衍生物的自乳化组合物和自乳化药物递送系统
WO2024210195A1 (ja) 2023-04-06 2024-10-10 Eaファーマ株式会社 炎症性腸疾患の治療用医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
NZ518888A (en) 1999-12-06 2004-02-27 F 4-pyridinyl-N-acyl-L-phenylalanines
WO2001056994A1 (en) 2000-02-04 2001-08-09 Biogen, Inc. Integrin antagonists
NZ524122A (en) 2000-08-18 2005-02-25 Ajinomoto Kk Phenylalanine derivatives useful as pharmaceutical agents
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
JP4233353B2 (ja) 2002-02-27 2009-03-04 田辺三菱製薬株式会社 医薬組成物
WO2005000244A2 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
WO2005061466A1 (ja) 2003-12-22 2005-07-07 Ajinomoto Co., Inc. 新規フェニルアラニン誘導体
EP1720839A1 (en) 2004-02-10 2006-11-15 Janssen Pharmaceutica N.V. Pyridazinones as antagonists of a4 integrins
JP2007532681A (ja) 2004-04-16 2007-11-15 ジェネンテック・インコーポレーテッド B細胞の枯渇を増大させる方法
US8030328B2 (en) 2005-05-20 2011-10-04 Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives
DK2842945T3 (da) * 2012-04-24 2017-01-30 Ea Pharma Co Ltd Sulfonamid-derivat og medicinsk anvendelse deraf
DE102013206014A1 (de) * 2013-04-05 2014-10-09 Dürr Systems GmbH Energiewandler-System und Baugruppen hierfür
BR112016009515B1 (pt) 2013-10-29 2022-05-03 EA Pharma Co., Ltd Derivado de sulfonamida, composição farmacêutica, agente terapêutico ou um agente preventivo para doença inflamatória, e, inibidor de integrina a4ß7

Also Published As

Publication number Publication date
TWI730042B (zh) 2021-06-11
TW201733991A (zh) 2017-10-01
KR20180104758A (ko) 2018-09-21
PL3412660T3 (pl) 2021-04-19
US20190040059A1 (en) 2019-02-07
HUE053354T2 (hu) 2021-06-28
AU2017214589B2 (en) 2020-09-03
MX381970B (es) 2025-03-04
JP6820282B2 (ja) 2021-01-27
EA201891780A1 (ru) 2019-02-28
PT3412660T (pt) 2021-01-13
AU2017214589A1 (en) 2018-08-16
EP3412660A1 (en) 2018-12-12
CN108699008A (zh) 2018-10-23
BR112018015855A2 (pt) 2018-12-26
WO2017135472A1 (ja) 2017-08-10
JPWO2017135472A1 (ja) 2018-11-29
CN108699008B (zh) 2021-10-08
KR102870086B1 (ko) 2025-10-16
EP3412660B9 (en) 2021-04-14
CA3013433A1 (en) 2017-08-10
EP3412660A4 (en) 2019-07-10
EA036432B1 (ru) 2020-11-10
US10562898B2 (en) 2020-02-18
MX2018009459A (es) 2018-09-21
EP3412660B1 (en) 2020-11-18
ES2856125T3 (es) 2021-09-27

Similar Documents

Publication Publication Date Title
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3347472T3 (da) Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf.
EP3493799A4 (en) CANNABIS
EP3513809A4 (en) MEDICAL COMPOSITION
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3655017T3 (da) Farmaceutisk sammensætning
IL256260B (en) Treprostinil derivatives and compositions and uses thereof
DK3603620T3 (da) Liposomsammensætning og farmaceutisk sammensætning
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
EP3493798A4 (en) CANNABIS
PT3500255T (pt) Composições farmacêuticas oftálmicas e utilizações relacionadas com estas
EP3454899C0 (en) PHARMACEUTICAL COMPOSITION
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
DK3399978T3 (da) Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3634377T3 (da) Farmaceutisk formulering
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3583943T3 (da) Farmaceutisk sammensætning
EP3402470A4 (en) STABLE PHARMACEUTICAL COMPOSITION
DK4023651T3 (da) Optisk aktivt pyranochromenylphenolderivat og farmaceutisk sammensætning, der omfatter samme
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
SMT202400478T1 (it) Composizione farmaceutica
EP3524250A4 (en) PHARMACEUTICAL COMPOSITION